Skip to main content
Top
Published in: Current Fungal Infection Reports 2/2014

01-06-2014 | Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)

Update on Posaconazole Pharmacokinetics: Comparison of Old and New Formulations

Authors: Kelly M. Percival, Scott J. Bergman

Published in: Current Fungal Infection Reports | Issue 2/2014

Login to get access

Abstract

Posaconazole is an extended-spectrum triazole antifungal that until recently was only available as an oral suspension. The absorption of this suspension is limited and is greatly affected by food, gastric pH, and intestinal motility. The systemic availability can be enhanced by administration with a high-fat meal, nutritional supplement, or acidic beverage, and by dividing into multiple daily doses. A new delayed-released tablet dosed once-daily has been developed and was recently approved by the U.S. Food and Drug Administration. This provides an attractive option for healthcare providers and patients because it has more predictable systemic availability and higher serum concentrations. However, the inability to crush or chew this tablet still leaves the need for another form of posaconazole, especially for critically ill patients. Such an option may soon become available, as a new drug application has been submitted to the FDA for a once-daily intravenous formulation of posaconazole.
Literature
1.
go back to reference Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49(6):379–96.PubMedCrossRef Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49(6):379–96.PubMedCrossRef
2.
go back to reference Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50(6):2009–15.PubMedCentralPubMedCrossRef Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50(6):2009–15.PubMedCentralPubMedCrossRef
3.
go back to reference Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12.PubMedCrossRef Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12.PubMedCrossRef
4.
go back to reference Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother. 2001;45(3):857–69.PubMedCentralPubMedCrossRef Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother. 2001;45(3):857–69.PubMedCentralPubMedCrossRef
5.
go back to reference Hernandez S, Gonzalez GM, McCarthy DI, Colombo AL, Najvar LK, Bocanegera R, et al. Alternatives to amphotericin B for Candida rugosa infection. J Antimicrob Chemother. 2004;54(2):477–80.PubMedCrossRef Hernandez S, Gonzalez GM, McCarthy DI, Colombo AL, Najvar LK, Bocanegera R, et al. Alternatives to amphotericin B for Candida rugosa infection. J Antimicrob Chemother. 2004;54(2):477–80.PubMedCrossRef
6.
go back to reference Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1996;40(8):1910–3.PubMedCentralPubMed Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1996;40(8):1910–3.PubMedCentralPubMed
7.
go back to reference Connolly P, Wheat J, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M, et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother. 1999;43(2):322–8.PubMedCentralPubMed Connolly P, Wheat J, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M, et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother. 1999;43(2):322–8.PubMedCentralPubMed
8.
go back to reference Restrepo A, Tobón A, Clark B, Graham DR, Corcoran G, Bradsher RW, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect. 2007;54(4):319–27.PubMedCrossRef Restrepo A, Tobón A, Clark B, Graham DR, Corcoran G, Bradsher RW, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect. 2007;54(4):319–27.PubMedCrossRef
9.
go back to reference Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother. 1996;40(5):1314–6.PubMedCentralPubMed Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother. 1996;40(5):1314–6.PubMedCentralPubMed
10.
go back to reference Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother. 1999;43(3):589–91.PubMedCentralPubMed Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother. 1999;43(3):589–91.PubMedCentralPubMed
11.
go back to reference Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46(7):2310–2.PubMedCentralPubMedCrossRef Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46(7):2310–2.PubMedCentralPubMedCrossRef
12.
go back to reference Lutz JE, Clemons KV, Aristizabal BH, Stevens DA. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother. 1997;41(7):1558–61.PubMedCentralPubMed Lutz JE, Clemons KV, Aristizabal BH, Stevens DA. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother. 1997;41(7):1558–61.PubMedCentralPubMed
13.
go back to reference Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21(5):645–53.PubMedCrossRef Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21(5):645–53.PubMedCrossRef
14.
go back to reference Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther. 2009;31(2):286–98.PubMedCrossRef Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther. 2009;31(2):286–98.PubMedCrossRef
15.
go back to reference Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004;32(2):267–71.PubMedCrossRef Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004;32(2):267–71.PubMedCrossRef
16.
go back to reference Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother. 2004;48(9):3543–51.PubMedCentralPubMedCrossRef Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother. 2004;48(9):3543–51.PubMedCentralPubMedCrossRef
17.
go back to reference Courtney R, Sansone A, Smith W, Marbury T, Statkevich P, Martinho M, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol. 2005;45(2):185–92.PubMedCrossRef Courtney R, Sansone A, Smith W, Marbury T, Statkevich P, Martinho M, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol. 2005;45(2):185–92.PubMedCrossRef
18.
go back to reference Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57(2):218–22.PubMedCentralPubMed Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57(2):218–22.PubMedCentralPubMed
19.
go back to reference Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47(9):2788–95.PubMedCentralPubMedCrossRef Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47(9):2788–95.PubMedCentralPubMedCrossRef
20.
go back to reference Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.PubMedCrossRef Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.PubMedCrossRef
21.
go back to reference Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.PubMedCrossRef Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.PubMedCrossRef
22.
go back to reference Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42(8):1179–86.PubMedCrossRef Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42(8):1179–86.PubMedCrossRef
23.
go back to reference Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44(4):607–14.PubMedCrossRef Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44(4):607–14.PubMedCrossRef
24.
go back to reference Posaconazole [package insert]. Whitehouse station. NJ: Merck & CO., INC.; 2013. Posaconazole [package insert]. Whitehouse station. NJ: Merck & CO., INC.; 2013.
25.
go back to reference Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126–33.PubMedCentralPubMedCrossRef Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126–33.PubMedCentralPubMedCrossRef
26.
go back to reference Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42(10):1398–403.PubMedCrossRef Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42(10):1398–403.PubMedCrossRef
27.
go back to reference Gubbins PO, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Martinho M, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother. 2006;50(6):1993–9.PubMedCentralPubMedCrossRef Gubbins PO, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Martinho M, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother. 2006;50(6):1993–9.PubMedCentralPubMedCrossRef
28.
go back to reference Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother. 2009;53(11):4749–52.PubMedCentralPubMedCrossRef Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother. 2009;53(11):4749–52.PubMedCentralPubMedCrossRef
29.
go back to reference Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. 2005;44(2):211–20.PubMedCrossRef Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. 2005;44(2):211–20.PubMedCrossRef
30.
go back to reference Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48(3):804–8.PubMedCentralPubMedCrossRef Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48(3):804–8.PubMedCentralPubMedCrossRef
31.
go back to reference Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet. 2011;50(11):725–34.PubMedCrossRef Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet. 2011;50(11):725–34.PubMedCrossRef
32.
go back to reference Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958–66.PubMedCentralPubMedCrossRef Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958–66.PubMedCentralPubMedCrossRef
33.
go back to reference Vehreschild JJ, Müller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987–95.PubMedCrossRef Vehreschild JJ, Müller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987–95.PubMedCrossRef
34.•
go back to reference Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(6):2806–13. Reviewed available data to recommend goals for therapeutic drug monitoirng of posaconaozle.PubMedCentralPubMedCrossRef Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(6):2806–13. Reviewed available data to recommend goals for therapeutic drug monitoirng of posaconaozle.PubMedCentralPubMedCrossRef
35.•
go back to reference Gross BN, Ihorst G, Jung M, Wäsch R, Engelhardt M. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy. 2013;33(10):1117–25. Described TDM in a real-life setting showing that a majority of patients have at least one level below the defined threshold for prophylaxis.PubMed Gross BN, Ihorst G, Jung M, Wäsch R, Engelhardt M. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy. 2013;33(10):1117–25. Described TDM in a real-life setting showing that a majority of patients have at least one level below the defined threshold for prophylaxis.PubMed
36.••
go back to reference Krishna G, Ma L, Martinho M, O'Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56(8):4196–201. First trial to describe the pharmacokinetics of the new tablet relative to the oral suspension.PubMedCentralPubMedCrossRef Krishna G, Ma L, Martinho M, O'Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56(8):4196–201. First trial to describe the pharmacokinetics of the new tablet relative to the oral suspension.PubMedCentralPubMedCrossRef
37.•
go back to reference Duarte RF, Lopez J, Cornely.O.A., L. M, M.P.S. vI, Waskins H. Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole (POS) Solid Oral Tablet in Patients at Risk for Invasive Fungal Infection (IFI). ICAAC; 2012; San Francisco, CA; 2012. Dose-determining study for delayed-release posaconazole tablets for prophylaxis of IFI. Duarte RF, Lopez J, Cornely.O.A., L. M, M.P.S. vI, Waskins H. Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole (POS) Solid Oral Tablet in Patients at Risk for Invasive Fungal Infection (IFI). ICAAC; 2012; San Francisco, CA; 2012. Dose-determining study for delayed-release posaconazole tablets for prophylaxis of IFI.
38.••
go back to reference Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67(11):2725–30. Evaluated the pharmacokinetics of single and multiple doses of a new formulation of posaconazole.PubMedCentralPubMedCrossRef Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67(11):2725–30. Evaluated the pharmacokinetics of single and multiple doses of a new formulation of posaconazole.PubMedCentralPubMedCrossRef
39.•
go back to reference Kraft WK, Chang P, van Iersel MPS, Waskin H, Krishna G, Kersemaekers W. Effect of Concomitant Medications Affecting Gastric pH and Motility on Posaconazole (POS) Tablet Pharmacokinetics (PK). ICAAC; 2012; San Francisco, CA; 2012. This study showed that the delayed-release tablets are not affected by reduced gastric pH or increased GI motility. Kraft WK, Chang P, van Iersel MPS, Waskin H, Krishna G, Kersemaekers W. Effect of Concomitant Medications Affecting Gastric pH and Motility on Posaconazole (POS) Tablet Pharmacokinetics (PK). ICAAC; 2012; San Francisco, CA; 2012. This study showed that the delayed-release tablets are not affected by reduced gastric pH or increased GI motility.
40.••
go back to reference Maertens J, Cornely O, Ullmann A, Heinz W, Krishna G, Kartsonis N, et al. Phase 1B Study of the Pharmacokinetics (PK) and Safety of Posaconazole (POS) IV in Patients (Pts) at Risk for Invasive Fungal Infection (IFI). ICAAC; 2012; San Francisco, CA; 2012. Dose determining study for intravenous posaconazole for prophylaxis of IFI. Maertens J, Cornely O, Ullmann A, Heinz W, Krishna G, Kartsonis N, et al. Phase 1B Study of the Pharmacokinetics (PK) and Safety of Posaconazole (POS) IV in Patients (Pts) at Risk for Invasive Fungal Infection (IFI). ICAAC; 2012; San Francisco, CA; 2012. Dose determining study for intravenous posaconazole for prophylaxis of IFI.
41.••
go back to reference Cornely OA, Haider S, Grigg A, van Iersel M, Caceres M, Hepler D, et al. Phase 3 Pharmacokinetics (PK) and Safety Study of Posaconazole (POS) IV in Patients (Pts) at Risk for Invasive Fungal Infection (IFI). ICAAC; 2013; Denver, CO; 2013. Described the pharmacokinetics of intravenous posaconazole at 300mg daily. Cornely OA, Haider S, Grigg A, van Iersel M, Caceres M, Hepler D, et al. Phase 3 Pharmacokinetics (PK) and Safety Study of Posaconazole (POS) IV in Patients (Pts) at Risk for Invasive Fungal Infection (IFI). ICAAC; 2013; Denver, CO; 2013. Described the pharmacokinetics of intravenous posaconazole at 300mg daily.
42.
go back to reference Nassander U, Kersemaekers W, van Iersel M, Xuan F, Caceres M, Waskine H. Pharmacokinetics (PK) and Safety Study of Posaconazole (POS) IV solution via Peripheral Administration in Healthy Subjects. ICAAC; 2013; Denver, CO; 2013. Nassander U, Kersemaekers W, van Iersel M, Xuan F, Caceres M, Waskine H. Pharmacokinetics (PK) and Safety Study of Posaconazole (POS) IV solution via Peripheral Administration in Healthy Subjects. ICAAC; 2013; Denver, CO; 2013.
Metadata
Title
Update on Posaconazole Pharmacokinetics: Comparison of Old and New Formulations
Authors
Kelly M. Percival
Scott J. Bergman
Publication date
01-06-2014
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 2/2014
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-014-0185-y

Other articles of this Issue 2/2014

Current Fungal Infection Reports 2/2014 Go to the issue

Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)

Amphotericin B: How Much Is Enough?

Translational Research (R Wheeler, Section Editor)

Essential Metals in Cryptococcus neoformans: Acquisition and Regulation

Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)

Cardiotoxicity Induced by Antifungal Drugs

Translational Research (R Wheeler, Section Editor)

Fine-Scale Chromosomal Changes in Fungal Fitness

Translational Research (R Wheeler, Section Editor)

To Sense or Die: Mechanisms of Temperature Sensing in Fungal Pathogens

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.